133 related articles for article (PubMed ID: 12456076)
1. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.
Rockenstein E; Mallory M; Mante M; Alford M; Windisch M; Moessler H; Masliah E
J Neural Transm Suppl; 2002; (62):327-36. PubMed ID: 12456076
[TBL] [Abstract][Full Text] [Related]
2. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.
Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E
J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.
Rockenstein E; Ubhi K; Pham E; Michael S; Doppler E; Novak P; Inglis C; Mante M; Adame A; Alvarez XA; Moessler H; Masliah E
J Neurosci Res; 2011 Nov; 89(11):1812-21. PubMed ID: 21793038
[TBL] [Abstract][Full Text] [Related]
4. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42).
Rockenstein E; Mallory M; Mante M; Sisk A; Masliaha E
J Neurosci Res; 2001 Nov; 66(4):573-82. PubMed ID: 11746377
[TBL] [Abstract][Full Text] [Related]
5. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
Rockenstein E; Adame A; Mante M; Larrea G; Crews L; Windisch M; Moessler H; Masliah E
J Neural Transm (Vienna); 2005 Feb; 112(2):269-82. PubMed ID: 15657642
[TBL] [Abstract][Full Text] [Related]
6. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.
Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E
Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
8. Early cortical thickness changes predict β-amyloid deposition in a mouse model of Alzheimer's disease.
Grand'maison M; Zehntner SP; Ho MK; Hébert F; Wood A; Carbonell F; Zijdenbos AP; Hamel E; Bedell BJ
Neurobiol Dis; 2013 Jun; 54():59-67. PubMed ID: 23454197
[TBL] [Abstract][Full Text] [Related]
9. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
[TBL] [Abstract][Full Text] [Related]
10. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression.
Cummings DM; Liu W; Portelius E; Bayram S; Yasvoina M; Ho SH; Smits H; Ali SS; Steinberg R; Pegasiou CM; James OT; Matarin M; Richardson JC; Zetterberg H; Blennow K; Hardy JA; Salih DA; Edwards FA
Brain; 2015 Jul; 138(Pt 7):1992-2004. PubMed ID: 25981962
[TBL] [Abstract][Full Text] [Related]
11. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
13. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease.
Matsuoka Y; Picciano M; La Francois J; Duff K
Neuroscience; 2001; 104(3):609-13. PubMed ID: 11440793
[TBL] [Abstract][Full Text] [Related]
14. Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.
Zeng Y; Zhang J; Zhu Y; Zhang J; Shen H; Lu J; Pan X; Lin N; Dai X; Zhou M; Chen X
J Neurochem; 2015 Apr; 133(1):38-52. PubMed ID: 25661995
[TBL] [Abstract][Full Text] [Related]
15. The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease.
Pimentel LS; Allard S; Do Carmo S; Weinreb O; Danik M; Hanzel CE; Youdim MB; Cuello AC
J Alzheimers Dis; 2015; 47(2):373-83. PubMed ID: 26401560
[TBL] [Abstract][Full Text] [Related]
16. Brainwide distribution and variance of amyloid-beta deposits in tg-ArcSwe mice.
Lillehaug S; Syverstad GH; Nilsson LN; Bjaalie JG; Leergaard TB; Torp R
Neurobiol Aging; 2014 Mar; 35(3):556-64. PubMed ID: 24126157
[TBL] [Abstract][Full Text] [Related]
17. Hyperspectral imaging signatures detect amyloidopathy in Alzheimer's mouse retina well before onset of cognitive decline.
More SS; Vince R
ACS Chem Neurosci; 2015 Feb; 6(2):306-15. PubMed ID: 25354367
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model.
Paban V; Manrique C; Filali M; Maunoir-Regimbal S; Fauvelle F; Alescio-Lautier B
Neuropharmacology; 2014 Jan; 76 Pt A():68-79. PubMed ID: 23891615
[TBL] [Abstract][Full Text] [Related]
20. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease.
Schmitz C; Rutten BP; Pielen A; Schäfer S; Wirths O; Tremp G; Czech C; Blanchard V; Multhaup G; Rezaie P; Korr H; Steinbusch HW; Pradier L; Bayer TA
Am J Pathol; 2004 Apr; 164(4):1495-502. PubMed ID: 15039236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
